Abstract: A method is provided utilizing contrast agents which provide increased diagnostic information in the magnetic resonance image of the hepatobiliary system and alimentary tract, especially the small intestine. Novel contrast agents which are N-carboxylated desferrioxamine B complexes with metal ions are provided.

Abstract: The present invention relates to contrast enhancing agents, conjugates thereof, pharmaceutical compositions thereof, and methods for diagnostic analysis, particularly NMR image analysis using these agents. The contrast enhancing agents are chelates of paramagnetic, ferromagnetic or diamagnetic metal ion(s) complexed with new lipophilic complexing acids related to polyaminopolycarboxylic acids.

Abstract: The use as a molluscicide of a chelate of aluminium (III) with a ligand of formula I or of iron (III) with a ligand of formula II[R.sup.1 COCHCOR.sup.2 ].sup.- I[R.sup.3 NO.N=O].sup.- IIwherein formulae II: R.sup.3 represents:C.sub.1 -C.sub.6 alkyl, provided that when the alkyl group contains more than four carbon atoms the group is a branched chain alkyl group.

Abstract: Compositions and methods for controlling intraocular pressure using transition metal complexes are disclosed. Topical ophthalmic and systemic administration of the transition metal complexes is disclosed.

Abstract: Biowaste treatment agents for treating biowastes in a manner which: (a) keeps noxious and toxic substances from being released from the biowaste, and (b) neutralizes such substances released during the course of stabilizing the biowaste. The treatment agents include a surfactant in an amount of from 1.0 to 99 percent of the treatment agent, a metal component in an amount from 0.5 to 85 percent of the treatment agent, the metal component including a source of zinc, or copper, or a combination of copper with aluminum or iron, and an aldehyde in an amount from 0.1 to 80 percent of the treatment agent.

Abstract: There is provided a magnetic resonance contrast medium comprising magnetically responsive particles and a physiologically tolerable osmoactive agent.

Abstract: A contrast enhancing agent for magnetic resonance images having a chelating agent, which can be bound to metals having at least one unpaired electron. Examples of such chelating agents include 3,6,9-tris(carboxymethyl)-1, 11-bis(dimethylamine)-3,6,9-triazaundecane; 3,6,9-tris(carboxymethyl)-1, 11-bis(diethanolamino) 3,6,9-triazaundecane; 3,6,9-tris(carboxymethyl)-1, 11-bis(tris(hydroymethyl) aminomethane)-3,6,9-triazaundecane; 3,6-bis(carboxymethyl-1,8-bis(N-carboxymethylglucosamino)-3,6-diazoctane; DTPA-bis(galactosamide), DTPA-Bis(glucosamide), DTPA-Bis(pyridoxamide), and poly-(DTPA-ethylenediamide).

Abstract: Hybrid agents for enhancing in vivo diagnostic imaging of body organs and tissues, and methods of preparing and using the same.

Abstract: An NMR contrast agent composition contains a complex of a selected metal ion and a selected ligand.

Abstract: Novel complexes of paramagnetic ions and compounds bearing long acyl chains have been synthesized as magnetic resonance imaging contrast agents. These novel liposoluble contrast agents may be administered alone, or with lipids, suspending agents or other additives. The lipids may be in the form of liposomes, micelles or lipid emulsions. The contrast agents of the invention have particular use in magnetic resonance imaging of the liver, blood pool and reticuloendothelial system.

Abstract: An NMR contrast agent composition contains a complex of a selected metal ion and a selected ligand.

Abstract: An environmentally compatible, non-phytotoxic anti-fungal composition is provided having an active ingredient which comprises a fatty acid metal salt having from 4 to 18 carbon atoms. The metal salt may be formed from metals including calcium, copper, magnesium, and zinc. Additional formulation enhancing agents, such as dispersants, wetting agents and gums, are typically included within the composition. The composition is advantageous in that it exhibits a residual fungicidal effect lasting up to 2 months.

Abstract: Pharmaceutically acceptable compositions of one or more n-6 or n-3 essential fatty acids, particularly gamma-linolenic acid, dihomo-gamma-linolenic acid, or eicosapentaenoic acid, and assimilable iron compounds, in dosage unit form optionally with a diluent or carrier, said acids being present as such or as derivatives convertible in the body thereto and the amounts of said acids or derivatives being 1 mg to 100 g (calculated as gamma-linolenic acid) and of said iron compounds 0.1 mg to 10 g (calculated as iron) or submultiples of said amounts convenient for daily administration thereof.

Abstract: The present invention relates to contrast enhancing agents, conjugates thereof, pharmaceutical compositions thereof, and methods for diagnostic analysis, particularly NMR image analysis using these agents. The contrast enhancing agents are chelates of paramagnetic, ferromagnetic or diamagnetic metal ion(s) complexed with new lipophilic complexing acids related to polyaminopolycarboxylic acids.

Abstract: The invention relates to an iron citrate micellar complex having a composition of 10.6% carbon, 2.62% hydrogen, 50.2% oxygen, 32% iron, and 4.6% sodium; a molecular weight of about 33,000 (HPLC-LALLS measurement); and the empirical formula (C.sub.31 H.sub.92 O.sub.110 Fe.sub.20 Na.sub.7).sub.n ; to a process for its production; and to its pharmaceutical use.

Abstract: Disclosed herein are copper based fungicidal and bactericidal compositions having enhanced activity against fungi and bacteria, methods of using such compositions as well as methods for increasing the effectiveness of the copper based fungicidal and/or bactericidal compounds employed in such compositions.

Abstract: The present invention relates to a process for the synthesis of monohaloalkanoylferrocenes of general formula (I) ##STR1## in which X=Cl, Br, n is an integer such that 2.ltoreq.n.ltoreq.7, R.sub.1 and R.sub.2 =H, C.sub.1 -C.sub.8 alkyl chain. A ferrocene derivative of general formula (II) ##STR2## in which R.sub.1 and R.sub.2 have the abovementioned meaning, is reacted at a temperature -5.degree. C.<.theta..sub.r <+15.degree. C., in the presence of AlCl.sub.3 with a halide or the anhydride of an acid of general formula (III) HOOC--(CH.sub.2).sub.n --X, X and n having the abovementioned meaning. An acylating solution obtained by mixing AlCl.sub.2 and the acid halide or anhydride in CH.sub.2 Cl.sub.2, whose temperature .theta..sub.a is such that 5.degree. C..ltoreq..theta..sub.r -.theta..sub.a .ltoreq.15.degree. C., is progressively added to a solution of the ferrocene derivative (II) in CH.sub.2 Cl.sub.2. The molar ratio of the acid halide or anhydride to the ferrocene derivative is between 0.99 and 1.

Abstract: Compounds having the formula R-(CH.sub.2).sub.m -CO-R' wherein R is ferrocene, a 5 to 7 member azacyclic system or an 8 to 11 member azabicyclic system, having 1 or 2 nitrogen atoms, or any such system substituted with one or more of F, Cl, Br, OH, C1 to C4 alkyl, C1 to C4 alkoxy, CF.sub.3, phenyl, amino, C1 to C4 alkylamino and di(C1 to C4 alkyl)amino; m is 0 or 1; and R' is--[NH(CH.sub.2).sub.n ].sub.x NH.sub.2, with each n being independently 2 to 5 and x being 1 to 6; ##STR1## with each n being independently 2 to 5, x being 0 to 4, y and z being independently 1 to 5 and the sum of x and the greater of y and z being 1 to 5; or ##STR2## with each a being 2 to 5, each b being 2 to 5, each n being independently 2 to 5, x being 0 to 3, each y being 0 or 1, z being 0 to 3 and x+y+z being 0 to 4, and their pharmaceutically acceptable acid addition salts are potent excitatory amino acid neurotransmitter antagonists.

Abstract: Methods for lowering elevated intraocular pressure resulting from the instillation to the eye of sodium hyaluronate during surgery by administration of transition metal complexes are disclosed.

Abstract: The present invention relates to a method for imparting insect repelling qualities to the hide or skin of animals by orally administering small but effective amounts of acetate salts to the animals, preferably on a daily basis.

Abstract: A method for maintaining the immune system of a warm-blooded animal afflicted with a form of antigenic morbidity exacerbated by intestinal malabsorption of minerals is disclosed. Minerals selected from the group consisting of copper, zinc, manganese, iron and selenium are provided in the form of amino acid chelates having a ligand to mineral ratio of at least 1:1, a molecular weight of no more than 1500 and a stability constant of between about 10.sup.6 and 10.sup.16 and administered orally. They are absorbed from a portion of the intestinal tract other than that utilized for the absorption of cations. The method is particularly adapted to the maintaining of the immune system of a warm-blooded animal infected by a virus which compromises the absorption of trace minerals via the normal cationic absorption route. The presence of intestinal malabsorption in the host showing symptoms of antigenic morbidity is first confirmed.

Abstract: There is described a preparation for iron supply comprising, as essential ingredients, a prescribed iron containing compound, sodium carbonate or sodium hydrogencarbonate and a neutralizing agent. This preparation is easily dissolved in water, and has a good taste so that it is agreeable to drinking, whereby sufficient amount of iron can suitably supplied to the living body. Also, there is described a preparation for iron supply or vitamin supply, to which potassium carbonate is added as a reservation stabilizing agent.

Abstract: The present invention relates to contrast enhancing agents, conjugates thereof, pharmaceutical compositions thereof, and methods for diagnostic analysis, particularly NMR image analysis using these agents. The contrast enhancing agents are chelates of paramagnetic, ferromagnetic or diamagnetic metal ion(s) complexed with new lipophilic complexing acids related to polyaminopolycarboxylic acids.

Abstract: An orally administered pharmaceutical agent that is particularly suited for iron and magnesium substitutive therapy is disclosed. This drug consists of a combination of one or more pharmaceutically and physiologically compatible iron compounds, one or more pharmaceutically and physiologically compatible magnesium compounds, and, if the magnesium compounds do not contain any chlorine atoms dissociable in aqueous media and saturating the available magnesium valences, the drug further consists of one or more pharmaceutically and physiologically compatible compounds providing chlorine ions in aqueous media. The iron compounds, magnesium compounds and chlorine ion supplying compounds may be mixed with the conventional pharmaceutical solvents and/or thinners and/or auxiliary matter. Unexpectedly, this drug makes it possible to simultaneously administer magnesium or calcium compounds with iron compounds, without thereby causing reduced iron resorption.

Abstract: Novel magnetic resonance imaging agents comprise complexes of paramagnetic ions with hydrazide derivatives of polyaminocarboxylic acid chelating agents. These novel imaging agents are characterized by excellent NMR image-contrasting properties and by high solubilities in physiological solutions. A novel method of performing an NMR diagnostic procedure involves administering to a warm-blooded animal an effective amount of a complex as described above and then exposing the warm-blooded animal to an NMR imaging procedure, thereby imaging at least a portion of the body of the warm-blooded animal.

Abstract: Fish feed and method for obtaining prophylactic effect on diseases where the bio-available Fe is reduced below 150 mg/kg and where there is established a synergetic effect when the Fe is used in combination with EPA/DHA or other n-3 poly-unsaturated fatty acids or derviatives in amounts up to 8.5% or higher.

Abstract: Pharmaceutically acceptable compositions of one or more n-6 or n-3 essential fatty acids, particularly gamma-linolenic acid, dihomo-gamma-linolenic acid, or eicosapentaenoic acid, and assimilable iron compounds, in dosage unit form optionally with a diluent or carrier, said acids being present as such or as derivatives convertible in the body thereto and the amounts of said acids or derivatives being 1 mg to 100 g (calculated as gamma-linolenic acid) and of said iron compounds 0.1 mg to 10 g (calculated as iron) or submultiples of said amounts convenient for daily administration thereof.

Abstract: A paramagnetic oil emulsion for magnetic resonance imaging composed of about 5 to about 30 volume percent oil and about 70 to about 95 volume percent aqueous-based paramagnetic agent carrier, at least one of the aqueous-based paramagnetic agent carrier and the oil having dissolved therein a magnetic resonance image contrast effective and less than a toxic amount of at least one soluble paramagnetic agent. The paramagnetic oil emulsion provides high intensity magnetic resonance signals in the gastrointestinal tract for MRI evaluation of the abdomen and pelvis, particularly in the distal bowel regions.

Abstract: Nutritional mineral supplements comprise iron compounds and calcium compounds in combination with citrates of tartrates, ascorbates, and, optionally, fructose. The tendency of calcium to inhibit the bio-availability is reduced in such compositions, so that conjoint bioavailability of these two important minerals is enhanced.

Abstract: 1-Aminocyclohexanecarboxylic acid derivatives of the formula I ##STR1## or their acid addition salts or a metal complex can be employed for protecting plants from microorganisms. In the formula I, R.sub.1 is hydrogen or C.sub.1 -C.sub.4 alkyl, R.sub.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, benzyl, or an ammonium radical which is unsubstituted or substituted by hydrocarbon radicals having not more than 20 C atoms, or a metal ion equivalent.Compounds of the formula I can be employed in the form of crop protection agents using suitable carrier materials.

Abstract: Injectable contrast agents of great clinical importance for lymphography, characterized by non-water soluble particle sizes between about 5 or 10 nm and about 500 or 900 nm, which have selective distribution to lymph nodes upon percutaneous administration and can be imaged with millimeter resolution. Also disclosed are methods for performing percutaneous lymphography using these contrast agents.

Abstract: There is described a preparation for iron supply comprising, as essential ingredients, a prescribed iron containing compound, sodium carbonate or sodium hydrogencarbonate and a neutralizing agent. This preparation is easily dissolved in water, and has a good taste so that it is agreeable to drinking, whereby a sufficient amount of iron can be suitably supplied to the living body. Also, there is described a preparation for iron supply or vitamin supply, to which potassium carbonate is added as a preservation stabilizing agent.

Abstract: The effects of acne and psoriasis are relived by applying either topically or by oral adminstration, a compound having the structure: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently selected from the group consisting of H, Cl, straight or branched alkyl of 1 to 10 carbon atoms, NO.sub.2, COOR.sub.6, CN, OR.sub.6, NR.sub.6 R.sub.7, NR.sub.6 C(.dbd.S)NR.sub.7 R.sub.8, NF.sub.6 COR.sub.7, SO.sub.2 NR.sub.6 R.sub.7, CH(CH.sub.3)COOH, CONR.sub.6 R.sub.7, COR.sub.6, OCONR.sub.6 R.sub.7, NR.sub.6 COONR.sub.7, R.sub.9 OR.sub.6, NR.sub.6 SO.sub.2 R.sub.7, Si(CH.sub.3).sub.3, and NR.sub.6 CONR.sub.7 R.sub.8,R.sub.3 together with R.sub.4 forms a benzo ring or taken together with R.sub.2 forms a benzo or tetrahydrobenzo ring or together with R.sub.2 and R.sub.1 forms a: ##STR2## moiety or together with R.sub.2 forms a ##STR3## moiety or R.sub.2 together with R.sub.1 forms a benzo ring or R.sub.2 together with R.sub.3 forms a ##STR4## moiety, or R.sub.

Abstract: A method is disclosed for the containment and controlled release of and the substantial reduction of the leaching from the site of application of agricultural chemicals. In the disclosed method, the agricultural chemicals are applied to the soil dispersed in an aqueous gel-forming composition. Novel compositions of the agricultural chemicals dispersed in aqueous gel-forming compositions are also disclosed.

Abstract: A method for the treatment of a patient comprises administering to said patient epidermal growth factor and an iron-providing material in order to effect an increase of the level of iron in the patient's bloodstream. The compositions may be administered parenteral, for example in intramuscular or oral form.

Abstract: Methods for preventing and treating oxidative insult to the eye by the administration of transition metal complexes are disclosed.

Abstract: Pharmaceutical compositions for the buccal or nasal administration of a neutral 3:1 hydroxypyrone:iron(III) complex of 3-hydroxy-4-pyrone or of a 3-hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms are of value for the treatment of iron deficiency anaemia.

Abstract: The present invention improves the safety of the use of sodium nitroprusside in the clinical setting. Specifically, this invention utilizes .alpha.-ketoglutaric acid or .alpha.-ketoglutaric acid and sodium thiosulfate to reduce sodium nitroprusside's toxic effects.

Abstract: New compounds having utility for enhancing the activity of antifolates are disclosed of the formula: ##STR1## wherein X is selected from hydrogen ##STR2## and R" ; R' is selected from alkyl, alkenyl, alkynyl, substituted and unsubstituted aryl, and substituted and unsubstituted heterocyclic aryl; R" is selected from ##STR3## and R'S; M is selected from OR and secondary amine; and R is selected from hydrogen, alkyl, acyloxymethyl, substituted and unsubstituted aryl, substituted and unsubstituted heterocyclic aryl, amino cation and metal cation.

Abstract: Nutritional mineral supplements comprise iron compounds and calcium compounds in combination with citrates or tartrates, ascorbates, and, optionally, fructose. The tendency of calcium to inhibit the bioavailability of iron is reduced in such compositions, so that conjoint bioavailability of these two important minerals is enhanced.

Abstract: Prolonged parenteral release of a bioactive polypeptide at desirably effective levels can be achieved using novel compositions in which the polypeptide is present in a biocompatible oil in an unusually high proportion such as at least about 10% by weight. Also disclosed are certain metal-associated somatotropins that are useful for prolonged parenteral release of such somatotropins.

Abstract: A composition including at least one salt of fumaric acid monoalkyl ester having the formula: ##STR1## alone or in combination with dialkyl fumarate having the formula: ##STR2## is provided for treatment of psoriasis and psoriatic arthritis. In particular, use of the calcium salt of fumaric acid monoalkyl ester in the composition is desirable.

Abstract: A method is disclosed for the containment and controlled release of and the substantial reduction of the leaching from the site of application of agricultural chemicals. In the disclosed method, the agricultural chemicals are applied to the soil dispersed in an aqueous gel-forming composition. Novel compositions of the agricultural chemicals dispersed in aqueous gel-forming compositions are also disclosed.

Abstract: A method has been discovered for the control of arthropod pests which comprises treating the pest with an effective amount of selected fluorocarbons.

Abstract: A new method of treating a burn is disclosed wherein a cobalt-containing metallo-organic complex is applied to the burn site to promote epithelialization and in some cases hair follicle preservation as well.

Abstract: A method of treating an inflammatory condition in a mammalian subject, particularly arthritis, comprising the steps of administering an effective and nontoxic dose for an inflammation ameliorating period to the subject of at least one metallo-organic complex capable of in vivo superoxide anti-oxidant effects and wherein the metal of the complex is selected from the group which consists of cobalt and iron.

Abstract: Amino acid chelates having a ligand to divalent metal mole ratio of at least 2:1 and having a molecular weight of not more than 1500 and preferably not more than 1000 and also having a stability constant of between about 10 and 10 are formulated for delivery to one or more specific tissue sites within a mammal. The ligand utilized in formulating the amino acid chelate is a naturally occuring amino acid or a dipeptide, tripeptide or quadrapeptide thereof. The selection of an appropriate ligand with which to form the chelate provides a product that, when entering the bloodstream of the mammal, either by mean of oral ingestion or injection, has a propensity to migrate to one or more targeted tissue sites within the mammal.

Abstract: Metallicenium salts of the general formula I[(.eta..sup.5 --C.sub.5 H.sub.-x R.sub.x)M(.eta..sup.5 --C.sub.5 H.sub.5-y R'.sub.y)].sub.a.sup.m+ [A].sub.b.sup.n- (I)in which M is Fe, Co, Ni, Ru or Os; C.sub.5 H.sub.5-x R.sub.x and C.sub.5 H.sub.5-y R'.sub.y denote cyclopendadienyl rings which, independently of one another, can be unsubstituted (x and y=0) or mono-, di-, tri-, tetra- or penta-substituted (x and y=1, 2, 3, 4 or 5), and in which R and R' independently of one another represent identical or different substituents and denote alkyl, cycloalkyl, hydroxyalkyl, aminoalkyl, halogenoalkyl, alkenyl, aryl, aralkyl, ferrocenyl, ferrocenylium, ferrocenylalkyl, acyl, halogenyl, trialkylsilyl, tricycloalkylsilyl, triarylsilyl, triaralkylsilyl or carboxyl, ester, amide or hydrazide groups, or R and R' together form an alkylene bridge with 2 to 4 bridge atoms; a, b, m and n are integers, and m has the value 1 or 2, n has the value 1, 2 or 3 and a.times.m=b.times.

Abstract: An oil based composition for the treatment of dry scalp conditions, dry skin conditions, and human hair is shown and decribed. This composition is made by placing grated avocado seed in a mineral oil solution for a period of time, straining the grated avocado seed from the mineral oil solution, and addition of other ingredients which include flowers of sulfur, castor oil, cod liver oil, peppermint spirit, orange water, spirit of camphor, and arnica.The composition described herein is used to treat dry scalp and skin conditions by placing the mixture on the treatment area for a substantial period of time and then shampooing it off.

Abstract: The disclosure is directed to compounds of the formula: ##STR1## wherein n=0, 1, 2, 3 or 4, and R.sub.1 and R.sub.2 may be the sam e or different and are selected from the group consisting of hydrogen and lower alkyl and hydroxy lower alkyl groups containing between 1 and 6 carbon atoms. Complexes of iron(II), iron(III), manganese(II), manganese(III), gadolinium(III), chromium(III), cobalt(II), and nickel(II) and such compounds are useful for enhancing magnetic resonance images of body organs and tissues. Illustrative complexes include (N,N"-bis[N-(2,3-dihydroxypropyl) carbamoylmethyl]diethylenetriamine-N,N',N"-triaceto)-iron(III), (N,N"-bis[N-(2,3-dihydroxypropyl)carbamoylmethyl]diethylenetriamine-N,N',N "-triaceto)manganese(II), (N,N"-bis[N-(2,3-dihydroxypropyl) )carbamoylmethyl]diethylenetriamine-N,N',N"-triaceto)gadolinium(III) and (N,N'-bis[N-(2,3-dihydroxypropyl)-carbamoylmethyl]ethylenediamine-N,N'-dia ceto)manganese(II).